Qiagen N.V. (NASDAQ:QGEN) Given “Neutral” Rating at Bank of America Corporation

Bank of America Corporation reaffirmed their neutral rating on shares of Qiagen N.V. (NASDAQ:QGEN) in a research report released on Friday, July 21st. Bank of America Corporation currently has a $36.00 price target on the stock, up from their previous price target of $33.00.

Other equities analysts also recently issued research reports about the company. TheStreet raised Qiagen N.V. from a c rating to a b rating in a research report on Monday, June 5th. Commerzbank Ag reaffirmed a buy rating on shares of Qiagen N.V. in a research report on Monday, May 29th. Barclays PLC reaffirmed a buy rating and issued a $33.00 target price on shares of Qiagen N.V. in a research report on Monday, May 15th. Deutsche Bank AG reaffirmed a buy rating on shares of Qiagen N.V. in a research report on Tuesday, May 2nd. Finally, BidaskClub cut Qiagen N.V. from a strong-buy rating to a buy rating in a research note on Saturday, June 10th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Qiagen N.V. presently has a consensus rating of Hold and a consensus target price of $33.17.

Shares of Qiagen N.V. (NASDAQ QGEN) traded down 0.85% during mid-day trading on Friday, hitting $31.36. The company’s stock had a trading volume of 603,125 shares. The company has a 50-day moving average of $33.30 and a 200 day moving average of $31.23. Qiagen N.V. has a 1-year low of $24.86 and a 1-year high of $35.26. The company has a market cap of $7.16 billion, a price-to-earnings ratio of 95.90 and a beta of 1.14.

Qiagen N.V. (NASDAQ:QGEN) last posted its earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The company had revenue of $349 million for the quarter, compared to the consensus estimate of $353.09 million. During the same quarter in the prior year, the business earned $0.24 earnings per share. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, analysts expect that Qiagen N.V. will post $1.23 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was reported by [[site]] and is the property of of [[site]]. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at [[permalink]].

A number of large investors have recently added to or reduced their stakes in QGEN. BlackRock Inc. boosted its stake in Qiagen N.V. by 4.6% in the second quarter. BlackRock Inc. now owns 8,203,013 shares of the company’s stock valued at $275,048,000 after buying an additional 363,377 shares during the last quarter. Vanguard Group Inc. boosted its stake in Qiagen N.V. by 7.0% in the second quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock valued at $202,986,000 after buying an additional 394,201 shares during the last quarter. Johnston Asset Management LLC boosted its stake in Qiagen N.V. by 1.1% in the second quarter. Johnston Asset Management LLC now owns 3,612,479 shares of the company’s stock valued at $121,126,000 after buying an additional 39,145 shares during the last quarter. Frontier Capital Management Co. LLC boosted its stake in Qiagen N.V. by 3.6% in the second quarter. Frontier Capital Management Co. LLC now owns 2,536,075 shares of the company’s stock valued at $85,035,000 after buying an additional 87,069 shares during the last quarter. Finally, State Street Corp boosted its stake in Qiagen N.V. by 2.1% in the second quarter. State Street Corp now owns 2,330,061 shares of the company’s stock valued at $78,130,000 after buying an additional 48,679 shares during the last quarter. Hedge funds and other institutional investors own 60.07% of the company’s stock.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.